AU772451B2 - Modified exosomes and uses - Google Patents

Modified exosomes and uses Download PDF

Info

Publication number
AU772451B2
AU772451B2 AU10514/00A AU1051400A AU772451B2 AU 772451 B2 AU772451 B2 AU 772451B2 AU 10514/00 A AU10514/00 A AU 10514/00A AU 1051400 A AU1051400 A AU 1051400A AU 772451 B2 AU772451 B2 AU 772451B2
Authority
AU
Australia
Prior art keywords
molecule
exosomes
cells
mhc
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU10514/00A
Other languages
English (en)
Other versions
AU1051400A (en
Inventor
Sebastian Amigorena
Philippe Benaroch
Christian Bonnerot
Graca Raposo
Pamela Stumptner
Helene Vincent-Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Curie filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU1051400A publication Critical patent/AU1051400A/en
Application granted granted Critical
Publication of AU772451B2 publication Critical patent/AU772451B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
AU10514/00A 1998-11-05 1999-11-04 Modified exosomes and uses Ceased AU772451B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9813946A FR2785543B1 (fr) 1998-11-05 1998-11-05 Exosomes modifies et utilisations
FR98/13946 1998-11-05
PCT/FR1999/002691 WO2000028001A1 (fr) 1998-11-05 1999-11-04 Exosomes modifies et utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004203482A Division AU2004203482A1 (en) 1998-11-05 2004-07-29 Modified exosomes and uses

Publications (2)

Publication Number Publication Date
AU1051400A AU1051400A (en) 2000-05-29
AU772451B2 true AU772451B2 (en) 2004-04-29

Family

ID=9532412

Family Applications (2)

Application Number Title Priority Date Filing Date
AU10514/00A Ceased AU772451B2 (en) 1998-11-05 1999-11-04 Modified exosomes and uses
AU2004203482A Withdrawn AU2004203482A1 (en) 1998-11-05 2004-07-29 Modified exosomes and uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2004203482A Withdrawn AU2004203482A1 (en) 1998-11-05 2004-07-29 Modified exosomes and uses

Country Status (10)

Country Link
EP (1) EP1127110A1 (fr)
JP (1) JP2002529074A (fr)
CN (1) CN1325441A (fr)
AU (2) AU772451B2 (fr)
CA (1) CA2349679A1 (fr)
EA (1) EA004428B1 (fr)
FR (1) FR2785543B1 (fr)
IL (1) IL142634A0 (fr)
TW (1) TWI224138B (fr)
WO (1) WO2000028001A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
IL160142A0 (en) 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
KR100519384B1 (ko) * 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
CN1313151C (zh) * 2002-11-04 2007-05-02 杭州浙大康泰生物技术有限公司 一种新型高效非细胞性疫苗的制备及其用途
JP4939926B2 (ja) 2003-02-14 2012-05-30 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
JPWO2005094571A1 (ja) * 2004-03-31 2008-02-14 独立行政法人科学技術振興機構 遺伝子改変ヘテロ動物及び該動物を用いたエキソサイトシスの計測方法
WO2006089572A1 (fr) * 2005-02-28 2006-08-31 Charité - Universitätsmedizin Berlin Capsules polyelectrolytiques de detection des reactions entre antigenes et anticorps
CN1322115C (zh) * 2005-07-06 2007-06-20 清华大学 载有外源配体分子的胞外体及其制备方法与应用
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CN101641010A (zh) 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 用作疫苗的外来体组分的修饰
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
CN102596177B (zh) * 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
KR20120081972A (ko) * 2009-07-02 2012-07-20 아이티에이치 임뮨 세라피 홀딩스 에이비 엑소좀에 기초한 암의 치료
ES2362589B1 (es) 2009-12-28 2012-05-16 Centre De Recerca En Salut Internacional De Barcelona Exosomas derivados de reticulocitos infectados con plasmodium sp., método para su obtención y su uso.
EP2785839A2 (fr) 2011-11-30 2014-10-08 University of Bremen Expression d'arnmi dans le tissu placentaire
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP3052616A4 (fr) * 2013-10-02 2017-03-29 Paradigm Biopharmaceuticals Limited Procédé de production d'exosomes
EP2862874B1 (fr) * 2013-10-15 2018-12-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Procédé de production d'anticorps polyclonaux à l'aide d'une composition antigénique comprenant des vésicules de membrane contenant des protéines
DE102014113688A1 (de) * 2014-09-22 2016-03-24 Jacobs University Bremen Ggmbh Antigenspezifische immunfärbung von t-zellen
WO2016149358A1 (fr) * 2015-03-16 2016-09-22 Duncan Ross Procédé de traitement comprenant des vésicules logées dans une membrane
RU2763524C2 (ru) * 2015-06-03 2021-12-30 Инновекс Терапеутикс, С.Л. Экзосомы и их применение в качестве вакцины
EP3307890A1 (fr) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Utilisation d'exosomes pour le traitement de maladies
AU2017226956A1 (en) 2016-03-03 2018-10-11 Institut Gustave Roussy PTPS-based vaccines against cancer
US20190112351A1 (en) 2016-04-04 2019-04-18 National Institutes Of Biomedical Innovation, Health And Nutrition Exosome-targeted dna vaccine
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
EP3801028A4 (fr) 2018-05-30 2022-04-13 Direct Biologics LLC Additif congelé ou en poudre de facteur de croissance et de vésicule extracellulaire comprenant une préparation de cellules souches mésenchymateuses (msc) et méthodes d'utilisation
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN110938670B (zh) * 2019-11-07 2023-11-07 南方医科大学南方医院 微生物菌液与血清囊泡反应在检测微生物感染中的应用
WO2021172595A1 (fr) * 2020-02-28 2021-09-02 国立大学法人金沢大学 Vésicule extracellulaire de présentation d'antigène, composition contenant celle-ci, et procédé destiné à la fabrication de celles-ci
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
JP2021000093A (ja) * 2020-08-05 2021-01-07 国立研究開発法人医薬基盤・健康・栄養研究所 エキソソーム標的ｄｎａワクチン
EP4537820A1 (fr) 2023-10-13 2025-04-16 Institut Gustave-Roussy Composé et combinaisons comprenant ledit composé pour améliorer une réponse immunitaire
EP4574155A1 (fr) 2023-12-22 2025-06-25 Christine Süßmuth Molécules destinées à être utilisées dans la régénération et le rajeunissement cellulaires
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005900A1 (fr) * 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Vesicules presentant des antigenes obtenues a partir de cellules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005900A1 (fr) * 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Vesicules presentant des antigenes obtenues a partir de cellules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAPOSO G ET AL (1997) MOL. BIOL. OF THE CELL 8:2631-45 *
ZITVOGEL L ET AL (1998) NATURE MEDICINE 4:594-600 *

Also Published As

Publication number Publication date
EP1127110A1 (fr) 2001-08-29
EA004428B1 (ru) 2004-04-29
WO2000028001A1 (fr) 2000-05-18
AU1051400A (en) 2000-05-29
AU2004203482A1 (en) 2004-08-26
CA2349679A1 (fr) 2000-05-18
CN1325441A (zh) 2001-12-05
TWI224138B (en) 2004-11-21
JP2002529074A (ja) 2002-09-10
FR2785543B1 (fr) 2003-02-28
FR2785543A1 (fr) 2000-05-12
EA200100509A1 (ru) 2001-12-24
IL142634A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
AU772451B2 (en) Modified exosomes and uses
AU2017312361B2 (en) T cell receptors and immune therapy using the same
Panté et al. Interactions and three-dimensional localization of a group of nuclear pore complex proteins.
EP3645573B1 (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
US11939376B2 (en) T cell receptors and immune therapy using the same
Rombout et al. Indications for a distinct putative T cell population in mucosal tissue of carp (Cyprinus carpio L.)
US20090304657A1 (en) Chimeric t cell receptors and related materials and methods of use
JP2002186486A (ja) Ｂ細胞上のｃｄ２８レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法
JPH09502096A (ja) 抗ｇｐ３９抗体およびその用途
De Bruijn et al. Mechanisms of induction of primary virus‐specific cytotoxic T lymphocyte responses
AU3062892A (en) Cd8 binding domain peptides
AU751151B2 (en) T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
CN110272482B (zh) 识别prame抗原短肽的t细胞受体
Matsuoka et al. A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement.
JPH10509948A (ja) Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法
WO1991016061A1 (fr) RECEPTEUR POLY-Ig SYNTHETIQUE, COMPLEXES RECEPTEURS-ANTICORPS, PRODUCTION ET UTILISATION
EP0503646A1 (fr) Anticorps monocloneaux dressés contre l'antigène-3 associé à la fonction lymphocyte
Egner et al. Dendritic cells have reduced cell surface membrane glycoproteins including CD43 determinants
EP3354658A1 (fr) Nouveaux récepteurs de cellules t et immunothérapie les utilisant pour le traitement du cancer et de maladies infectieuses
Andersson et al. Surface glycoproteins of resting and activated human T lymphocytes
Kane et al. Class I alloantigen is sufficient for cytolytic T lymphocyte binding and transmembrane signaling
EP3978520A1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
Jardieu et al. Relationship among IgE-binding factors with various molecular weights.
CN120718134B (zh) 靶向col6a3肽的t细胞受体及其用途
WO1996012009A2 (fr) Procedes de genie genetique permettant la realisation de cellules presentant des antigenes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)